Research map: Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives

Back to the article

Papers in this map

  1. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality · The Emerging Risk Factors Collaboration* · 2009 · 1758 citations · Cited by this paper
  2. Advancing Human Placental Modeling Through Stem-Cell-Derived Trophoblast Organoids and Reprogramming Innovations · 2026 · Related
  3. A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM · Kåre Berg · 1963 · 1379 citations · Cited by this paper
  4. The Role of Endothelial–Mesenchymal Transition (EndMT) in Aneurysm Formation · 2026 · Related
  5. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease · Sotirios Tsimikas · 2020 · 1081 citations · Cited by this paper
  6. Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model · 2026 · Related
  7. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk · Michelle L. O’Donoghue · 2019 · 1001 citations · Cited by this paper
  8. Differential Protective Actions of Dulaglutide and Dexamethasone in Methotrexate Induced Pulmonary Fibrosis: Relationship with AMPK and Beclin-1 Levels · 2026 · Related
  9. Evinacumab for Homozygous Familial Hypercholesterolemia · Frederick Johan Raal · 2020 · 797 citations · Cited by this paper
  10. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies · 2026 · Related
  11. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study · Marina Cuchel · 2012 · 753 citations · Cited by this paper
  12. Evaluation of Early and Delayed Meloxicam Treatment Against Regulated Cell Death Pathways and ERK1/2 Phosphorylation in a Rat Model of Renal Ischemia–Reperfusion Injury · 2026 · Related
  13. Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023 · Benjamin A. Stark · 2025 · 612 citations · Cited by this paper
  14. Overcoming mTOR Inhibitor Resistance: From Biological Basis to Therapeutic Strategies · 2026 · Related
  15. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias · François Mach · 2025 · 601 citations · Cited by this paper
  16. Region-Specific Proteomic Profiles of Extracellular Vesicles (EVs) Derived from Human Macular and Peripheral RPE-Choroid Explants · 2026 · Related
  17. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease · Aniruddh P. Patel · 2020 · 558 citations · Cited by this paper
  18. Bioactive Metabolites of Solanum tuberosum L. in Inflammation Modulation and Tissue Regeneration: A Scoping Review of Wound Healing Mechanisms · 2026 · Related
  19. Statin therapy increases lipoprotein(a) levels · Sotirios Tsimikas · 2019 · 518 citations · Cited by this paper
  20. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk · Amit Khera · 2013 · 463 citations · Cited by this paper
  21. Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis · Kang H. Zheng · 2019 · 341 citations · Cited by this paper
  22. Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels · Connor A. Emdin · 2016 · 257 citations · Cited by this paper
  23. Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease · Michelle L. O’Donoghue · 2013 · 215 citations · Cited by this paper
  24. Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis · Alexander H. Nave · 2015 · 200 citations · Cited by this paper
  25. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome · Gregory G. Schwartz · 2020 · 193 citations · Cited by this paper
  26. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial · Stephen James Nicholls · 2022 · 176 citations · Cited by this paper
  27. The LDL cumulative exposure hypothesis: evidence and practical applications · Brian A. Ference · 2024 · 169 citations · Cited by this paper
  28. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds · Sotirios Tsimikas · 2022 · 150 citations · Cited by this paper
  29. Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program) · Daniel Gaudet · 2016 · 131 citations · Cited by this paper
  30. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature · Ellie Paige · 2017 · 123 citations · Cited by this paper
  31. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective · Benoît J. Arsenault · 2022 · 123 citations · Cited by this paper
  32. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study · Nicolas Perrot · 2016 · 119 citations · Cited by this paper
  33. Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease · Adam N. Berman · 2024 · 116 citations · Cited by this paper
  34. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events · Peter Engel Thomas · 2023 · 100 citations · Cited by this paper
  35. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome · Gregory G. Schwartz · 2017 · 97 citations · Cited by this paper
  36. Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation · Nick S. Nurmohamed · 2024 · 94 citations · Cited by this paper
  37. Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis · Michael Torzewski · 2017 · 89 citations · Cited by this paper
  38. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis · Calvin Yeang · 2016 · 88 citations · Cited by this paper
  39. Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis · Pradeep Kumar · 2021 · 76 citations · Cited by this paper

Source: OpenAlex (CC0)